Market News

Qurate Retail Group, Inc. (QRTEA) EPS Estimated At $0.62; Vaxart (VXRT) Shorts Decreased By 61.75%

Vaxart Inc (NASDAQ:VXRT) had a decrease of 61.75% in short interest. VXRT’s SI was 15,300 shares in April as released by FINRA. Its down 61.75% from 40,000 shares previously. With 24,000 avg volume, 1 days are for Vaxart Inc (NASDAQ:VXRT)’s short sellers to cover VXRT’s short positions. The stock increased 1.86% or $0.0998 during the last trading session, reaching $5.4698. About 88,218 shares traded or 55.66% up from the average. Vaxart, Inc. (NASDAQ:VXRT) has declined 25.31% since April 19, 2017 and is downtrending. It has underperformed by 36.86% the S&P500.

Analysts expect Qurate Retail Group, Inc. (NASDAQ:QRTEA) to report $0.62 EPS on May, 10 before the open.They anticipate $0.25 EPS change or 67.57% from last quarter’s $0.37 EPS. QRTEA’s profit would be $296.44 million giving it 10.24 P/E if the $0.62 EPS is correct. After having $2.12 EPS previously, Qurate Retail Group, Inc.’s analysts see -70.75% EPS growth. The stock decreased 0.37% or $0.095 during the last trading session, reaching $25.405. About 853,620 shares traded. Qurate Retail Group, Inc. (NASDAQ:QRTEA) has 0.00% since April 19, 2017 and is . It has underperformed by 11.55% the S&P500.

Qurate Retail Group, Inc. markets and sells various consumer products primarily through live merchandise-focused televised shopping programs, Websites, and mobile applications. The company has market cap of $12.15 billion. The company's Websites offers home, apparel, beauty, accessories, jewelry, and electronics products. It has a 9.41 P/E ratio. It also operates as an online retailer of women's, children's, and men's apparel, and children's merchandise; and home, beauty, and personalized products, as well as retails its products through catalogs, and retail and outlet stores.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company has market cap of $39.05 million. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus vaccines, as well as other recombinant vaccines. It currently has negative earnings. The Company’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV.

Leave a Reply

Your email address will not be published. Required fields are marked *